Stonepine Capital Management LLC Has $1.65 Million Stock Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Stonepine Capital Management LLC cut its position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 73.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 663,405 shares of the biotechnology company’s stock after selling 1,795,468 shares during the period. Aclaris Therapeutics accounts for approximately 1.3% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 23rd biggest holding. Stonepine Capital Management LLC owned about 0.93% of Aclaris Therapeutics worth $1,645,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in ACRS. ExodusPoint Capital Management LP acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $26,000. Invesco Ltd. acquired a new stake in shares of Aclaris Therapeutics in the 4th quarter valued at about $28,000. Graham Capital Management L.P. bought a new position in Aclaris Therapeutics in the 4th quarter valued at about $35,000. Commonwealth Equity Services LLC bought a new position in Aclaris Therapeutics in the 4th quarter valued at about $36,000. Finally, Alpine Global Management LLC bought a new position in Aclaris Therapeutics in the 4th quarter valued at about $38,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $1.31 on Friday. The firm has a market cap of $141.85 million, a price-to-earnings ratio of -2.52 and a beta of 0.42. Aclaris Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $5.17. The firm has a 50-day moving average price of $1.36 and a two-hundred day moving average price of $2.23.

Aclaris Therapeutics (NASDAQ:ACRS) last posted its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. As a group, sell-side analysts forecast that Aclaris Therapeutics, Inc. will post -0.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ACRS. Scotiabank dropped their price target on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a “sector outperform” rating on the stock in a research report on Friday, May 9th. Cantor Fitzgerald began coverage on shares of Aclaris Therapeutics in a research report on Tuesday, March 18th. They issued an “overweight” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target (down previously from $20.00) on shares of Aclaris Therapeutics in a research report on Wednesday. Finally, StockNews.com cut shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 8th. One equities research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $10.00.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.